Brain+

0.01 DKK

+4.00 %

Less than 1K followers

BRAINP

First North Denmark

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+4.00 %

-20.00 %

-21.21 %

-24.64 %

-77.70 %

-78.62 %

-98.43 %

-

-99.24 %

Brain+ are a pharmaceutical company. The company specializes in research and development for the treatment of dementia and Alzheimer's. The product portfolio includes, for example, cognitive stimulation therapy. In addition to the main business, service and associated ancillary services are also offered. The business is run with the largest presence in Europe. Brain+ is headquartered in Copenhagen.

Market cap

11.78M DKK

Turnover

15.25K DKK

Revenue

200K

EBIT %

-5,830 %

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

All

Press releases

3rd party

ShowingAll content types

Press release14 hours ago

Brain+ Investor Update - November

Regulatory press release11/19/2025, 11:24 AM

Brain+ A/S updates its financial guidance for 2025

Press release11/6/2025, 2:13 PM

Brain+ investor update — October

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release10/31/2025, 7:00 AM

BRAIN+ UPDATES ITS COMMUNICATION POLICY AS THE COMPANY MOVES INTO A NEW COMMERCIALISATION PHASE

Regulatory press release10/6/2025, 6:20 AM

Brain+ appoints new Chief Financial Officer

Press release9/24/2025, 6:36 AM

Brain+ launches first Ayla NHS pilot with one of the UK’s largest primary care practices

Press release9/16/2025, 7:21 AM

Brain+ signs agreement with Agincare Homes – the fourth UK care home group to deploy effective dementia therapy with Ayla

Regulatory press release9/15/2025, 9:41 AM

The Chief Financial Officer to transition, replacement search has been initiated

Press release9/4/2025, 9:58 AM

Clinical pilot of Ayla based dementia therapy (CST) improves cognitive outcome by nearly 50% in care home residents

Press release9/2/2025, 7:44 AM

Brain+ expands its agreement with Southcare Homes Group to deploy Ayla across the group

Press release9/1/2025, 6:41 AM

Brain+ invites investors and other stakeholders to a webinar for a presentation of its Half Year 2025 report

Regulatory press release8/28/2025, 9:23 PM

Brain+ publishes Half Year Report for 2025

Regulatory press release6/24/2025, 12:11 PM

Brain+ A/S announces first day of trading in new shares following the TO 5 warrant exercise

Regulatory press release6/18/2025, 9:22 AM

Brain+ A/S announces the outcome of its series TO 5 warrant exercise

Regulatory press release6/10/2025, 7:58 AM

Brain+ A/S has received commitments to cover 100% of its TO 5 warrants, securing DKK 5.9 million in gross proceeds

Press release6/6/2025, 2:56 PM

Invitation to investor webinar featuring Antony Hall: How new CST evidence and UK dementia care quality focus underscore the relevance and potential of Ayla

Press release6/6/2025, 8:51 AM

New research underscores the effects of Cognitive Stimulation Therapy, supporting its role for UK care homes to comply with care quality statements

Press release6/5/2025, 9:49 AM

Brain+ signs agreement with UK care home group Majesticare deploying Ayla for effective dementia care

Regulatory press release6/2/2025, 1:49 PM

Brain+ A/S announces the exercise price for its warrants of series TO 5

Regulatory press release5/30/2025, 2:22 PM

Brain+ A/S - Minutes of Annual General Meeting

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.